Literature DB >> 8537648

Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model.

G S Giebink1, J D Meier, M K Quartey, C L Liebeler, C T Le.   

Abstract

Cross-protection among pneumococcal serotypes within serogroups was measured in the chinchilla otitis media (OM) model because several serotypes that cause OM in children are closely related biochemically. Chinchillas were given tetravalent vaccine composed of pneumococcal capsular polysaccharides (PS; types 6B, 14, 19F, 23F) conjugated to an outer membrane protein complex, and 89% to 96% developed a > or = 2-fold serum IgG rise against vaccine PS. Vaccine efficacy was tested by inoculating middle ear hypotympanic bullae with Streptococcus pneumoniae types 6B, 6A, 19F, or 19A. OM severity in the vaccinated groups challenged with types 6B, 6A, and 19F but not 19A was significantly better than in the respective placebo groups. Culture-positive pneumococcal OM occurred in 38%, 62%, 0, and 78% of vaccinated chinchillas challenged with types 6B, 6A, 19F, and 19A, respectively, but in 88% of type 6B- and 100% of type 6A-, 19A-, and 19F-challenged placebo chinchillas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8537648     DOI: 10.1093/infdis/173.1.119

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Evaluation of serotype prediction by cpsA-cpsB gene polymorphism in Streptococcus pneumoniae.

Authors:  E R Lawrence; C A Arias; B Duke; D Beste; K Broughton; A Efstratiou; R C George; L M Hall
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

2.  Pneumococcal carriage in children in The Netherlands: a molecular epidemiological study.

Authors:  D Bogaert; M N Engelen; A J Timmers-Reker; K P Elzenaar; P G Peerbooms; R A Coutinho; R de Groot; P W Hermans
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

3.  Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity to serotype 19A in a murine pneumococcal pneumonia model.

Authors:  Håvard Jakobsen; Viktor D Sigurdsson; Sigurveig Sigurdardottir; Dominique Schulz; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

4.  Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine.

Authors:  S Zielen; I Bühring; N Strnad; J Reichenbach; D Hofmann
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

5.  Differential uptake and processing of a Haemophilus influenzae P5-derived immunogen by chinchilla dendritic cells.

Authors:  Laura A Novotny; Santiago Partida-Sánchez; Robert S Munson; Lauren O Bakaletz
Journal:  Infect Immun       Date:  2007-12-26       Impact factor: 3.441

Review 6.  New vaccines for the prevention of pneumococcal infections.

Authors:  H Käyhty; J Eskola
Journal:  Emerg Infect Dis       Date:  1996 Oct-Dec       Impact factor: 6.883

7.  Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice.

Authors:  Håvard Jakobsen; Stefania Bjarnarson; Giuseppe Del Giudice; Monique Moreau; Claire-Anne Siegrist; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.